In a 78-year-old man with diabetes mellitus, hypertension, and hyperlipidemia who is on rosuvastatin 10 mg and has a low‑density lipoprotein cholesterol of 155 mg/dL, how should his lipid‑lowering therapy be intensified?

Intensify to Rosuvastatin 20 mg Daily

In this 78-year-old man with diabetes, hypertension, and hyperlipidemia on rosuvastatin 10 mg with an LDL-C of 155 mg/dL, increase rosuvastatin to 20 mg daily to achieve high-intensity statin therapy. This patient requires aggressive LDL-lowering given his diabetes and multiple cardiovascular risk factors.

Rationale for High-Intensity Statin Therapy

This patient with diabetes mellitus is automatically classified as high-risk for atherosclerotic cardiovascular disease (ASCVD), regardless of calculated risk scores 1. The 2020 ADA Standards of Care explicitly state that for patients with diabetes at higher risk—particularly those aged 50-70 years with multiple ASCVD risk factors—high-intensity statin therapy is reasonable to reduce LDL-C by ≥50% 1.

The 2018 ACC/AHA Cholesterol Guidelines similarly recommend that in patients 40-75 years with diabetes and LDL-C ≥70 mg/dL, clinicians should consider high-intensity statin therapy, especially in those with multiple risk factors 2. This patient's LDL-C of 155 mg/dL is more than double the threshold, making the case for intensification compelling.

Dose Escalation Strategy

• Current therapy: Rosuvastatin 10 mg is moderate-intensity statin therapy
• Target therapy: Rosuvastatin 20 mg achieves high-intensity statin therapy
• Expected LDL reduction: Doubling the rosuvastatin dose provides an additional 4.5% LDL-C reduction 3, and rosuvastatin 20 mg typically achieves approximately 50% LDL reduction from baseline 4

The FDA labeling confirms rosuvastatin is well-tolerated across the dose range, with maximum LDL-C reduction typically achieved by 4 weeks 5.

Target LDL-C Goals

While the primary goal is achieving ≥50% LDL reduction with high-intensity statin therapy 1, the absolute LDL-C target for this diabetic patient should be:

• Primary target: <100 mg/dL (standard for diabetes) 1
• Optimal target: <70 mg/dL (if very high-risk features present) 2, 1

Monitoring and Next Steps

Reassess lipid panel in 4-12 weeks after dose increase 1. If LDL-C remains ≥100 mg/dL on rosuvastatin 20 mg:

1. First addition: Ezetimibe 10 mg daily—this is the preferred next step due to lower cost and proven cardiovascular benefit 1
2. If LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe, consider PCSK9 inhibitor 2, 1

Safety Considerations in Older Adults

At age 78, this patient warrants specific attention:

• The ADA guidelines note that heterogeneity by age has not been seen in the relative benefit of lipid-lowering therapy, and absolute benefits are actually greater in older adults due to higher baseline risk 1
• Rosuvastatin pharmacokinetics show no differences between elderly and non-elderly populations 5
• Monitor for myopathy risk, which increases with age ≥65 years 5—counsel patient to report unexplained muscle pain, tenderness, or weakness immediately
• Check baseline and follow-up liver function tests and creatine kinase if symptoms develop 5

Common Pitfalls to Avoid

• Don't remain on moderate-intensity therapy when high-intensity is indicated—this patient's LDL-C of 155 mg/dL on rosuvastatin 10 mg demonstrates inadequate response
• Don't jump to combination therapy before maximizing statin intensity—dose escalation should precede adding ezetimibe 2, 1
• Don't use age alone as a reason to avoid intensification—the evidence supports aggressive lipid management in older adults with diabetes 1
• Don't forget lifestyle modification—continue emphasizing heart-healthy diet and exercise alongside pharmacotherapy 2